ArticleCell reports2019
Molecularly Distinct Clathrin-Coated Pits Differentially Impact EGFR Fate and Signaling.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 89 citations in OpenAlex.
- Phosphoglycerate kinase 1 cooperates with the AP2 complex to promote endocytosis.EMBO reports · 2026Article
- Functional Specialization of Clathrin-Independent Endocytic Routes: Mechanisms and Cellular Roles.Traffic (Copenhagen, Denmark) · 2026Review
- Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.Research square · 2026Article
- Identification and functional validation of EPS15L1 as a key driver of triple-negative breast cancer.NPJ breast cancer · 2026Article
- Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis, and diminishes cell motility signaling.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Small-molecule CBLB inhibitor abolishes EGFR ubiquitination, reduces receptor endocytosis and diminishes cell motility signaling.bioRxiv : the preprint server for biology · 2026Article
- Article
- Canonical tyrosine-based motifs are required for constitutive endocytosis and polarity of IRT1 and contribute to metal uptake.The Plant journal : for cell and molecular biology · 2025Article
- LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer.International journal of oral science · 2025Article
- DNAJC5 facilitates the proliferation and migration of lung adenocarcinoma cells by augmenting EGFR trafficking.Communications biology · 2025Article
- Single influenza A viruses induce nanoscale cellular reprogramming at the virus-cell interface.Nature communications · 2025Article
- The essential clathrin adapter protein complex-2 is tumor suppressive specifically in vivo.Nature communications · 2025Article
- Clathrin-associated carriers enable recycling through a kiss-and-run mechanism.Nature cell biology · 2024Article
- Reduction of endocytosis and EGFR signaling is associated with the switch from isolated to clustered apoptosis during epithelial tissue remodeling in Drosophila.PLoS biology · 2024Article
- EGFR-dependent endocytosis of Wnt9a and Fzd9b promotes β-catenin signaling during hematopoietic stem cell development in zebrafish.Science signaling · 2024Article
- Downregulation of praja2 restrains endocytosis and boosts tyrosine kinase receptors in kidney cancer.Communications biology · 2024Article
- Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.International journal of molecular sciences · 2024Article
- Therapeutic potential of ADAM10 modulation in Alzheimer's disease: a review of the current evidence.Cell communication and signaling : CCS · 2023Review
- Imaging nanoscale axial dynamics at the basal plasma membrane.The international journal of biochemistry & cell biology · 2023Review
- Clathrin mediates both internalization and vesicular release of triggered T cell receptor at the immunological synapse.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 7 institutions in 4 countries.
Roberta PascoluttiIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.
Veronica AlgisiIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.
Alexia ConteIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Andrea RaimondiExperimental Imaging Centre, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy.
Mithun PashamProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Srigokul UpadhyayulaProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.
Raphael GaudinProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA; Institut de Recherche en Infectiologie de Montpellier, UMR 9004, CNRS/UM, 1919 route de Mende, 34293 Montpellier cedex 5, France.
Tanja MaritzenLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany.
Elisa BarbieriIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Giusi CaldieriIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy.
Chiara TordonatoIstituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Stefano ConfalonieriIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Stefano FreddiIstituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy.
Maria Grazia MalabarbaIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy.
Elena MasperoIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy.
Simona PoloIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy.
Carlo TacchettiExperimental Imaging Centre, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
Volker HauckeLeibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Straße 10, 13125 Berlin, Germany.
Tom KirchhausenProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Pier Paolo Di FioreIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy.
Sara SigismundIFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy; Istituto Europeo di Oncologia IRCCS, Via Ripamonti 435, 20141 Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-oncologia, Via Santa Sofia 9/1, 20122 Milan, Italy. Electronic address: sara.sigismund@ieo.it.
IFOM · ITUniversity of Milan · ITBoston Children's Hospital · USLeibniz-Forschungsinstitut für Molekulare Pharmakologie · DERipamonti · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITVita-Salute San Raffaele University · IT
Funding
Small-molecule inhibitors of flavivirus entryU19AI109740 · NIAID · HARVARD MEDICAL SCHOOL · PI CUNNINGHAM, JAMES · 2014 to 2018
$23.0MDynamics of Clathrin Coat Formation in CellsR01GM075252 · NIGMS · IMMUNE DISEASE INSTITUTE, INC. · PI KIRCHHAUSEN, TOMAS · 2005 to 2018
$4.6MVISUALIZATION OF SUBCELLULAR DYNAMICS IN MULTICELLULAR ORGANISMSR35GM130386 · NIGMS · BOSTON CHILDREN'S HOSPITAL · PI TOMAS KIRCHHAUSEN · 2019 to 2026
$4.0MHoward Hughes Medical InstituteNIAID NIH HHS U19 AI109740NIGMS NIH HHS R01 GM075252NIGMS NIH HHS R35 GM130386Worldwide Cancer Research 16-1245
Abstract
Adaptor protein 2 (AP2) is a major constituent of clathrin-coated pits (CCPs). Whether it is essential for all forms of clathrin-mediated endocytosis (CME) in mammalian cells is an open issue. Here, we demonstrate, by live TIRF microscopy, the existence of a subclass of relatively short-lived CCPs lacking AP2 under physiological, unperturbed conditions. This subclass is retained in AP2-knockout cells and is able to support the internalization of epidermal growth factor receptor (EGFR) but not of transferrin receptor (TfR). The AP2-independent internalization mechanism relies on the endocytic adaptors eps15, eps15L1, and epsin1. The absence of AP2 impairs the recycling of the EGFR to the cell surface, thereby augmenting its degradation. Accordingly, under conditions of AP2 ablation, we detected dampening of EGFR-dependent AKT signaling and cell migration, arguing that distinct classes of CCPs could provide specialized functions in regulating EGFR recycling and signaling.
Indexed as
Signal TransductionAdaptor Protein Complex 2Adaptor Proteins, Signal TransducingAdaptor Proteins, Vesicular TransportAnimalsCell LineCell MovementClathrin-Coated VesiclesEndocytosisEpidermal Growth FactorErbB ReceptorsGene EditingHeLa CellsHumansMiceMicroscopy, FluorescenceAdaptor Protein Complex 2Adaptor Proteins, Signal TransducingAdaptor Proteins, Vesicular TransportEGFR protein, humanEpidermal Growth FactorEPS15 protein, humanepsinErbB ReceptorsProto-Oncogene Proteins c-aktRNA, Small InterferingAP2clathrin-coated pitsEGFRendocytic adaptorsendocytosiseps15epsinreceptor degradationrecyclingsignalingtranscription
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.